Europe has approved teclistamab plus daratumumab after MajesTEC-3 showed an 83.4% reduction in progression or death and a significant overall-survival advantage versus established regimens.
Discover how wearable injectors could reshape multiple myeloma treatment, clinic capacity and the competitive battle between Sarclisa and daratumumab.
FDA approves TECVAYLI plus DARZALEX FASPRO for relapsed multiple myeloma. Discover what the MajesTEC-3 data means for future immunotherapy strategies.
FDA approves J&J's teclistamab plus daratumumab for relapsed myeloma from second line. Analyse the MajesTEC-3 data, safety profile, and what this changes for treatment.
Find out how DARZALEX FASPRO’s FDA approval for transplant-ineligible myeloma patients could shift frontline treatment standards.
TECVAYLI and DARZALEX FASPRO show major survival benefits in second-line multiple myeloma. Find out what the MajesTEC-3 trial means for clinical practice.